<DOC>
	<DOC>NCT00097539</DOC>
	<brief_summary>The purpose of this multicenter, open-label, observational, post-marketing surveillance study is to collect long term safety and efficacy information on growth hormone (GH) products: Protropin (somatrem for injection), Nutropin (somatropin for injection), Nutropin AQ (somatropin for injection), and Nutropin Depot (somatropin for injectable suspension) in the treatment of pediatric growth disorders for which GH is prescribed.</brief_summary>
	<brief_title>National Cooperative Growth Study (NCGS): A Post-marketing Surveillance Program for Nutropin, Nutropin AQ, Nutropin Depot, and Protropin</brief_title>
	<detailed_description />
	<mesh_term>Growth Disorders</mesh_term>
	<criteria>Participants with open epiphyses Children of either sex who are treated with Nutropin Depot, Nutropin AQ, Nutropin, or Protropin for the treatment of growth failure Participants who are willing to keep follow up appointments throughout the study participation Participants treated with a nonGenentech GH preparation Participants with closed epiphyses Participants with active neoplasia</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Pediatric growth disorders</keyword>
</DOC>